Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
1.
Int J Urol ; 31(6): 637-645, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38380475

ABSTRACT

OBJECTIVES: This work aims to assess the diagnostic value of chromogranin A (CgA) in the laboratory diagnosis of neuroendocrine tumors classified as pheochromocytoma and paraganglioma (PPGL). METHODS: A comprehensive search was performed in PubMed, Embase, the Cochrane Library, and Web of Science databases to obtain relevant studies reporting the diagnostic accuracy of CgA in patients with PPGL. The search involved studies written in English between the time of library inception and May 1, 2023. We computed the pooled sensitivity, specificity, and diagnostic odds ratio (DOR). Additionally, the receiver operating characteristic curve and area under the curve (AUC) were determined. The heterogeneity was assessed using the Chi-square test and the I2 test. The subgroup analyses were performed to investigate the origins of heterogeneity. Stata 15.1 statistical software was used in all data analyses. RESULTS: This meta-analysis included 13 studies involving 1470 patients. CgA had a pooled diagnostic sensitivity of 0.86 (95% CI 0.81-0.91), a specificity of 0.90 (95% CI 0.81-0.95), and a DOR of 57 (95% CI 23-142). CgA had an AUC of 0.93. The studies did not reveal any threshold effect (r = -0.165; p > 0.05). The subgroup analyses revealed that the control group category and the detection method caused the overall heterogeneity. CONCLUSIONS: Our study suggests that CgA is a helpful PPGL biomarker. However, relying solely on CgA for diagnosis is not advisable. A comprehensive approach is essential for accurate diagnosis. Future large-scale research is needed to refine CgA's clinical application.


Subject(s)
Adrenal Gland Neoplasms , Biomarkers, Tumor , Chromogranin A , Paraganglioma , Pheochromocytoma , Sensitivity and Specificity , Humans , Pheochromocytoma/diagnosis , Pheochromocytoma/blood , Chromogranin A/blood , Chromogranin A/analysis , Adrenal Gland Neoplasms/diagnosis , Adrenal Gland Neoplasms/blood , Paraganglioma/diagnosis , Paraganglioma/blood , Biomarkers, Tumor/blood , Biomarkers, Tumor/analysis , ROC Curve
2.
Scand J Clin Lab Invest ; 81(7): 564-572, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34570657

ABSTRACT

BACKGROUND: Accurate diagnosis of pheochromocytoma and paraganglioma (PPGLs) is highly dependent on the detection of metanephrines and catecholamines. However, the systematic investigation on influencing factors including specimen (plasma or whole blood), anticoagulant, storage conditions, and interference factors need further confirmation. METHODS: Blood with heparin-lithium or EDTA-K2 were collected, stability of epinephrine (EPI), norepinephrine (NE), dopamine (DA), metanephrine (MN), normetanephrine (NMN), 3-methoxytyramine (3-MT) in whole blood and plasma at room temperature and 4 °C for different storage times, stability of plasma MN, NMN and 3-MT at -20 °C and -80 °C were investigated. Plasma with hemoglobin (1 g/L, 2 g/L, 3 g/L, 4 g/L, 6 g/L), TG (<5 mmol/L, 5-8 mmol/L, >8 mmol/L) were prepared. RESULTS: EPI, NE, DA were prone to degrade at room temperature, samples should be centrifuged at 4 °C. EPI and NE were stable in whole blood at 4 °C for 4 h and in plasma for 2 h. For MN, NMN, 3-MT, plasma can be stable at room temperature and 4 °C for at least 6 h, which is better than whole blood; there was no significant difference when stored at -20 °C and -80 °C for 7 days. Heparin-lithium had a slight advantage over EDTA-K2. EPI, NE, DA should not be performed when Hb > 1 g/L or TG > 5 mmol/L. MN, NMN, 3-MT should not be performed when Hb > 2 g/L, whereas TG had no interference. CONCLUSIONS: According to the actual clinical application scenario, this study provided a reliable basis for the accurate diagnosis of PPGLs.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Catecholamines/blood , Dopamine/analogs & derivatives , Metanephrine/blood , Paraganglioma/diagnosis , Pheochromocytoma/diagnosis , Adrenal Gland Neoplasms/blood , Anticoagulants/pharmacology , Dopamine/blood , Epinephrine/blood , Hemoglobins/analysis , Humans , Metabolome , Norepinephrine/blood , Normetanephrine/blood , Paraganglioma/blood , Pheochromocytoma/blood , Triglycerides/blood
3.
Front Endocrinol (Lausanne) ; 12: 722656, 2021.
Article in English | MEDLINE | ID: mdl-34557163

ABSTRACT

Context: Pheochromocytomas and paragangliomas (PPGL) cause catecholamine excess leading to a characteristic clinical phenotype. Intra-individual changes at metabolome level have been described after surgical PPGL removal. The value of metabolomics for the diagnosis of PPGL has not been studied yet. Objective: Evaluation of quantitative metabolomics as a diagnostic tool for PPGL. Design: Targeted metabolomics by liquid chromatography-tandem mass spectrometry of plasma specimens and statistical modeling using ML-based feature selection approaches in a clinically well characterized cohort study. Patients: Prospectively enrolled patients (n=36, 17 female) from the Prospective Monoamine-producing Tumor Study (PMT) with hormonally active PPGL and 36 matched controls in whom PPGL was rigorously excluded. Results: Among 188 measured metabolites, only without considering false discovery rate, 4 exhibited statistically significant differences between patients with PPGL and controls (histidine p=0.004, threonine p=0.008, lyso PC a C28:0 p=0.044, sum of hexoses p=0.018). Weak, but significant correlations for histidine, threonine and lyso PC a C28:0 with total urine catecholamine levels were identified. Only the sum of hexoses (reflecting glucose) showed significant correlations with plasma metanephrines.By using ML-based feature selection approaches, we identified diagnostic signatures which all exhibited low accuracy and sensitivity. The best predictive value (sensitivity 87.5%, accuracy 67.3%) was obtained by using Gradient Boosting Machine Modelling. Conclusions: The diabetogenic effect of catecholamine excess dominates the plasma metabolome in PPGL patients. While curative surgery for PPGL led to normalization of catecholamine-induced alterations of metabolomics in individual patients, plasma metabolomics are not useful for diagnostic purposes, most likely due to inter-individual variability.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Blood Cells/metabolism , Metabolome , Paraganglioma/diagnosis , Pheochromocytoma/diagnosis , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/metabolism , Adult , Blood Chemical Analysis/methods , Case-Control Studies , Catecholamines/metabolism , Chromatography, Liquid , Female , Germany , Humans , Male , Metabolomics/methods , Middle Aged , Paraganglioma/blood , Paraganglioma/metabolism , Pheochromocytoma/blood , Pheochromocytoma/metabolism , Tandem Mass Spectrometry
4.
Sci Rep ; 11(1): 14706, 2021 07 19.
Article in English | MEDLINE | ID: mdl-34282182

ABSTRACT

Diagnosis of pheochromocytomas and paragangliomas in patients receiving hemodialysis is troublesome. The aim of the study was to establish optimal conditions for blood sampling for mass spectrometric measurements of normetanephrine, metanephrine and 3-methoxytyramine in patients on hemodialysis and specific reference intervals for plasma metanephrines under the most optimal sampling conditions. Blood was sampled before and near the end of dialysis, including different sampling sites in 170 patients on hemodialysis. Plasma normetanephrine concentrations were lower (P < 0.0001) and metanephrine concentrations higher (P < 0.0001) in shunt than in venous blood, with no differences for 3-methoxytyramine. Normetanephrine, metanephrine and 3-methoxytyramine concentrations in shunt and venous blood were lower (P < 0.0001) near the end than before hemodialysis. Upper cut-offs for normetanephrine were 34% lower when the blood was drawn from the shunt and near the end of hemodialysis compared to blood drawn before hemodialysis. This study establishes optimal sampling conditions using blood from the dialysis shunt near the end of hemodialysis with optimal reference intervals for plasma metanephrines for the diagnosis of pheochromocytomas/paragangliomas among patients on hemodialysis.


Subject(s)
Blood Specimen Collection , Metanephrine/blood , Renal Dialysis , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/diagnosis , Aged , Aged, 80 and over , Blood Chemical Analysis/methods , Blood Chemical Analysis/standards , Blood Specimen Collection/methods , Blood Specimen Collection/standards , Calibration , Dopamine/analogs & derivatives , Dopamine/analysis , Dopamine/blood , Female , Humans , Male , Metanephrine/analysis , Middle Aged , Paraganglioma/blood , Paraganglioma/diagnosis , Pheochromocytoma/blood , Pheochromocytoma/diagnosis , Poland , Pre-Analytical Phase/methods , Pre-Analytical Phase/standards , Reference Values , Tandem Mass Spectrometry/methods , Tandem Mass Spectrometry/standards
5.
J Clin Endocrinol Metab ; 106(10): e4028-e4038, 2021 09 27.
Article in English | MEDLINE | ID: mdl-34089611

ABSTRACT

CONTEXT: Pheochromocytomas and paragangliomas (PCC/PGL) are neuroendocrine tumors with discrete catecholamine profiles that cause incompletely understood metabolic and physiologic changes. OBJECTIVE: The objective was to evaluate relationships between plasma catecholamines, body weight, and hemoglobin A1c (HbA1c). We hypothesized that individual catecholamines would correlate negatively with weight and glucose control. DESIGN: A retrospective cohort study was performed (1999-2020). Wilcoxon rank-sum tests compared nonparametric, continuous variables; mixed-effect linear modeling (MEM) evaluated relationships between catecholamines and weight or HbA1c. The median study duration was 54.2 months [interquartile range (IQR) 19.0-95.1]. SETTING: Tertiary academic hospital. PATIENTS: 360 patients were identified prospectively by referral to our center for management or surveillance of PCC/PGL. The median age was 59 years (IQR 45-67) and 56.4% (n = 203) were female. MAIN OUTCOME MEASURES: The primary and secondary outcomes were weight and HbA1c, respectively. RESULTS: On multivariable MEM, norepinephrine (P < 0.0005) negatively correlated with weight when all catecholamines and their derivatives were tried in the model, and normetanephrine (P < 0.0005) correlated when only metanephrines were included. In the surgical cohort (n = 272), normetanephrine decreased postoperatively and was inversely associated with weight (P < 0.0005). Elevated norepinephrine or normetanephrine at the study termination, indicative of metastatic and/or recurrent disease (MRD), correlated with weight loss. Norepinephrine and normetanephrine (P < 0.0005) directly correlated with HbA1c. CONCLUSION: Plasma norepinephrine and its metabolite directly correlate with HbA1c and inversely correlate with weight in PCC/PGL. After resection, declining normetanephrine levels correlate with improving HbA1c despite an increase in patient body weight. Persistently elevated catecholamines and decreasing weight are observed in MRD.


Subject(s)
Adrenal Gland Neoplasms , Body Weight/physiology , Catecholamines/blood , Diabetes Mellitus/epidemiology , Paraganglioma , Pheochromocytoma , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/complications , Adrenal Gland Neoplasms/epidemiology , Aged , Cohort Studies , Diabetes Mellitus/blood , Diabetes Mellitus/etiology , Female , Glycated Hemoglobin/metabolism , Humans , Male , Middle Aged , Obesity/blood , Obesity/epidemiology , Obesity/etiology , Paraganglioma/blood , Paraganglioma/complications , Paraganglioma/epidemiology , Pheochromocytoma/blood , Pheochromocytoma/complications , Pheochromocytoma/epidemiology , Retrospective Studies , Risk Factors , United States/epidemiology
6.
J Clin Endocrinol Metab ; 106(8): e2900-e2906, 2021 07 13.
Article in English | MEDLINE | ID: mdl-33846745

ABSTRACT

CONTEXT: False-positive results are common for pheochromocytoma/paraganglioma (PPGL) real-world screening. OBJECTIVE: Determine the correlation between screening urine and seated plasma metanephrines in outpatients where PPGL was absent, compared to meticulously prepared and supine-collected plasma metanephrines with age-adjusted references. DESIGN: Retrospective cohort study. SETTING: Databases from a single-provider provincial laboratory (2012-2018), a validated PPGL registry, and a manual chart review from a specialized endocrine testing unit. PATIENTS: PPGL registry data excluded known PPGL cases from the laboratory database. Outpatients having both urine and plasma metanephrines <90 days apart. METHODS: The correlation between urine and seated plasma measures along with the total positivity rate. All cases of plasma metanephrines drawn in the endocrine unit were reviewed for test indication and test positivity rate. RESULTS: There were 810 non-PPGL pairs of urine and plasma metanephrines in the laboratory database; 46.1% of urine metanephrines were reported high. Of seated outpatient plasma metanephrines drawn a median of 5.9 days later, 19.2% were also high (r = 0.33 and 0.50 for normetanephrine and metanephrine, respectively). In contrast, the meticulously prepared and supine collected patients (n = 139, 51% prior high urine metanephrines) had <3% rate of abnormal high results in patients without known PPGL/adrenal mass. CONCLUSIONS: There was a poor-to-moderate correlation between urine and seated plasma metanephrines. Up to 20% of those with high urine measures also had high seated plasma metanephrines in the absence of PPGL. Properly prepared and collected supine plasma metanephrines had a false-positive rate of <3% in the absence of known PPGL/adrenal mass.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Metanephrine/blood , Paraganglioma/diagnosis , Pheochromocytoma/diagnosis , Adolescent , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/urine , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Biomarkers, Tumor/urine , Diagnosis, Differential , False Positive Reactions , Female , Humans , Male , Mass Screening , Metanephrine/urine , Middle Aged , Paraganglioma/blood , Paraganglioma/pathology , Paraganglioma/urine , Pheochromocytoma/blood , Pheochromocytoma/pathology , Pheochromocytoma/urine , Retrospective Studies , Sensitivity and Specificity , Young Adult
7.
Blood Press ; 30(3): 172-179, 2021 06.
Article in English | MEDLINE | ID: mdl-33586556

ABSTRACT

PURPOSE: Current evidence regarding renal involvement in pheochromocytoma and paraganglioma (PPGL) is scant. More accurate diagnostic methods, such as renal Doppler ultrasound for intrarenal hemodynamic studies, may provide more detailed information on renal function. It might be postulated that renal function in PPGL patients might be altered by high blood pressure and excess secretion of catecholamines. The aim of this prospective study was to assess intrarenal blood flow parameters in PPGL patients included in the prospective monoamine-producing tumour (PMT) study and to evaluate the effects of normalisation of catecholamine production after surgical treatment on long-term renal function. MATERIALS AND METHODS: Seventy consecutive patients (aged 46.5 ± 14.0 years) with PPGL were included. Forty-eight patients from the PMT study cohort, matched for age, gender, blood pressure level and presence of hypertension, served as a control group. Renal artery doppler ultrasound spectral analysis included mean resistance index (RRI) and pulsatility index (PI). Forty-seven patients completed 12 months follow-up. RESULTS: There were no differences in renal parameters such as RRI, PI and kidney function between PPGL and non-PPGL patients as assessed by renal ultrasound, serum creatinine, eGFR and albumin excretion rate. No correlations between kidney function parameters, intrarenal doppler flow parameters and plasma catecholamines were observed in PPGL patients. At 12 months after surgery, no differences in creatinine level, eGFR, albumin excretion rate, RI and PI were found as compared to baseline results. CONCLUSIONS: In contrast to patients with other forms of secondary hypertension, our study did not show differences in intrarenal blood flow parameters and renal function between PPGL and non-PPGL subjects. Intrarenal hemodynamics and renal function did not change after normalisation of catecholamine levels by surgical treatment.


Subject(s)
Adrenal Gland Neoplasms/surgery , Hemodynamics , Kidney , Paraganglioma/surgery , Pheochromocytoma/surgery , Ultrasonography, Doppler , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/diagnostic imaging , Adult , Cross-Sectional Studies , Female , Humans , Kidney/blood supply , Kidney/diagnostic imaging , Kidney/metabolism , Kidney/physiopathology , Kidney Function Tests , Male , Middle Aged , Paraganglioma/blood , Paraganglioma/diagnostic imaging , Pheochromocytoma/blood , Pheochromocytoma/diagnostic imaging , Retrospective Studies
8.
Clin Biochem ; 87: 67-73, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33096053

ABSTRACT

OBJECTIVE: To verify a rapid and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the quantification of catecholamines and their metabolites, and to validate its efficiency for the diagnosis of phaeochromocytomas and paragangliomas (PPGLs). METHODS: Plasma samples were pretreated with solid-phase extraction, followed by a 3-min UPLC-MS/MS analysis to quantify epinephrine (E), norepinephrine (NE), dopamine (DA), metanephrine (MN), normetanephrine (NMN) and 3-methoxytyramine (3-MT), simultaneously. The UPLC-MS/MS method was comprehensively verified and its diagnostic efficiency on PPGLs was tested using 7 PPGLs and 408 non-PPGLs patient plasma samples. RESULTS: Using the developed method, the limit of detections (LODs) of the 6 analytes ranged from 0.0002 nmol/L (MN) to 0.0250 nmol/L (NE), while the lower limit of measuring intervals (LLMIs) ranged from 0.05 nmol/L (E, MN and NMN) to 0.10 nmol/L (NE and DA). The reportable ranges were 0.05-30.00 nmol/L for E, MN and NMN, 0.10-30.00 nmol/L for NE and DA, 1.00-300.00 pg/mL for 3-MT. No significant matrix effect was detected after correcting using internal standard. Besides, intra-day and inter-day precision were also within acceptance criteria with coefficient of variations (CVs) ≤ 15% and recoveries ranged from 95% to 115% for all the 6 analytes. The carryover effect was lower than 10%. Its diagnostic efficiency for PPGLs was significantly increased, the areas under the receiver operating characteristic (ROC) curves were increased from 68.7% to 89.1% (using E, NE and DA) to 75.2%-99.9% (using MN, NMN and 3-MT). CONCLUSION: This study verified a rapid UPLC-MS/MS method for the determination of catecholamines and their metabolites in human plasma. It showed high diagnostic efficiency and will serve as an important tool to avoid the risk for missing patients with PPGLs.


Subject(s)
Catecholamines/blood , Chromatography, Liquid/methods , Paraganglioma/diagnosis , Pheochromocytoma/diagnosis , Tandem Mass Spectrometry/methods , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/diagnosis , Calibration , Dopamine/analogs & derivatives , Dopamine/metabolism , Female , Humans , Limit of Detection , Male , Metanephrine/metabolism , Norepinephrine/blood , Normetanephrine/metabolism , Paraganglioma/blood , Pheochromocytoma/blood , ROC Curve
10.
J Clin Endocrinol Metab ; 105(9)2020 09 01.
Article in English | MEDLINE | ID: mdl-32609829

ABSTRACT

CONTEXT: Catecholamines and adrenocortical steroids are important regulators of blood pressure. Bidirectional relationships between adrenal steroids and catecholamines have been established but whether this is relevant to patients with pheochromocytoma is unclear. OBJECTIVE: This study addresses the hypothesis that patients with pheochromocytoma and paraganglioma (PPGL) have altered steroid production compared with patients with primary hypertension. DESIGN: Multicenter cross-sectional study. SETTING: Twelve European referral centers. PATIENTS: Subjects included 182 patients with pheochromocytoma, 36 with paraganglioma and 270 patients with primary hypertension. Patients with primary aldosteronism (n = 461) and Cushing syndrome (n = 124) were included for additional comparisons. INTERVENTION: In patients with PPGLs, surgical resection of tumors. OUTCOME MEASURES: Differences in mass spectrometry-based profiles of 15 adrenal steroids between groups and after surgical resection of PPGLs. Relationships of steroids to plasma and urinary metanephrines and urinary catecholamines. RESULTS: Patients with pheochromocytoma had higher (P < .05) circulating concentrations of cortisol, 11-deoxycortisol, 11-deoxycorticosterone, and corticosterone than patients with primary hypertension. Concentrations of cortisol, 11-deoxycortisol, and corticosterone were also higher (P < .05) in patients with pheochromocytoma than with paraganglioma. These steroids correlated positively with plasma and urinary metanephrines and catecholamines in patients with pheochromocytoma, but not paraganglioma. After adrenalectomy, there were significant decreases in cortisol, 11-deoxycortisol, corticosterone, 11-deoxycorticosterone, aldosterone, and 18-oxocortisol. CONCLUSIONS: This is the first large study in patients with PPGLs that supports in a clinical setting the concept of adrenal cortical-medullary interactions involving an influence of catecholamines on adrenal steroids. These findings could have implications for the cardiovascular complications of PPGLs and the clinical management of patients with the tumors.


Subject(s)
Adrenal Gland Neoplasms/blood , Glucocorticoids/blood , Hypertension/blood , Paraganglioma/blood , Pheochromocytoma/blood , Adrenal Gland Neoplasms/complications , Adrenal Gland Neoplasms/physiopathology , Adrenal Gland Neoplasms/surgery , Adult , Aged , Cross-Sectional Studies , Europe/epidemiology , Female , Humans , Hyperaldosteronism/etiology , Hyperaldosteronism/metabolism , Hyperaldosteronism/physiopathology , Hyperaldosteronism/surgery , Hypertension/etiology , Hypertension/physiopathology , Hypertension/surgery , Male , Middle Aged , Paraganglioma/complications , Paraganglioma/physiopathology , Paraganglioma/surgery , Pheochromocytoma/complications , Pheochromocytoma/physiopathology , Pheochromocytoma/surgery , Retrospective Studies
11.
Eur J Endocrinol ; 183(2): 129-139, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32413848

ABSTRACT

BACKGROUND: In patients with phaeochromocytomas or paragangliomas (PPGLs), 24-h urine collections for metanephrines (uMNs) are cumbersome. OBJECTIVE: To evaluate the diagnostic utility of ratios to creatinine of 'spot' uMNs. METHODS: Concentrations of uMNs and plasma metanephrines (pMNs) were measured by HPLC-mass-spectrometry. We retrospectively compared correlations of 24-h-urine output and ratio to creatinine in historical specimens and prospectively assessed 24-h and contemporaneous spot urines and, where possible, pMNs. Using trimmed log-transformed values, we derived reference intervals based on age and sex for spot urines. We used multiples of upper limit of normal (ULNs) to compare areas under curves (AUCs) for receiver-operator characteristic curves of individual, and sum and product of, components. RESULTS: In 3143 24-h-urine specimens on 2416 patients, the correlation coefficients between the ratios and outputs of metanephrine, normetanephrine and 3-methoxytyramine in 24-h urines were 0.983, 0.905 and 0.875, respectively. In 96 patients, the correlations between plasma concentrations, urine output and ratios in spot specimens were similar to those for raw output or ratios in 24-h specimens. Of the 160 patients with PPGLs, the CIs for AUCs for individual metabolites overlapped for all four types of measurement, as did those for the sum of the multiple ULNs although these were slightly higher (AUC for spot urine: 0.838 (0.529-1), plasma: 0.929 (0.874-0.984) and output: 0.858 (0.764-0.952)). CONCLUSIONS: Ratios of fractionated metanephrines to creatinine in spot urine samples appear to have a similar diagnostic power to other measurements. The ease of spot urine collection may facilitate diagnosis and follow-up of PPGLs through improved patient compliance.


Subject(s)
Adrenal Gland Neoplasms/urine , Metanephrine/blood , Metanephrine/urine , Paraganglioma/urine , Pheochromocytoma/urine , Adolescent , Adrenal Gland Neoplasms/blood , Adult , Age Factors , Aged , Aged, 80 and over , Area Under Curve , Chromatography, High Pressure Liquid , Creatinine/blood , Creatinine/urine , Dopamine/analogs & derivatives , Dopamine/blood , Dopamine/urine , Female , Humans , Male , Mass Spectrometry , Middle Aged , Normetanephrine/blood , Normetanephrine/urine , Paraganglioma/blood , Pheochromocytoma/blood , ROC Curve , Reference Values , Retrospective Studies , Sex Factors , Young Adult
13.
Eur J Endocrinol ; 181(4): 409-420, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31370000

ABSTRACT

OBJECTIVE: Hypertension and symptoms of catecholamine excess are features of pheochromocytomas and paragangliomas (PPGLs). This prospective observational cohort study assessed whether differences in presenting features in patients tested for PPGLs might assist establishing likelihood of disease. DESIGN AND METHODS: Patients were tested for PPGLs because of signs and symptoms, an incidental mass on imaging or routine surveillance due to previous history or hereditary risk. Patients with (n = 245) compared to without (n = 1820) PPGLs were identified on follow-up. Differences in presenting features were then examined to assess the probability of disease and relationships to catecholamine excess. RESULTS: Hyperhidrosis, palpitations, pallor, tremor and nausea were 30-90% more prevalent (P < 0.001) among patients with than without PPGLs, whereas headache, flushing and other symptoms showed little or no differences. Although heart rates were higher (P < 0.0001) in patients with than without PPGLs, blood pressures were not higher and were positively correlated to BMI, which was lower (P < 0.0001) in patients with than without PPGLs. From these differences in clinical features, a score system was established that indicated a 5.8-fold higher probability of PPGLs in patients with high than low scores. Higher scores among patients with PPGLs were associated, independently of tumor size, with higher biochemical indices of catecholamine excess. CONCLUSIONS: This study identifies a complex of five signs and symptoms combined with lower BMI and elevated heart rate as key features in patients with PPGLs. Prevalences of these features, which reflect variable tumoral catecholamine production, may be used to triage patients according to likelihood of disease.


Subject(s)
Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/diagnosis , Catecholamines/blood , Paraganglioma/blood , Paraganglioma/diagnosis , Pheochromocytoma/blood , Pheochromocytoma/diagnosis , Adrenal Gland Neoplasms/epidemiology , Cohort Studies , Female , Humans , Male , Middle Aged , Paraganglioma/epidemiology , Pheochromocytoma/epidemiology , Prospective Studies
14.
Eur J Endocrinol ; 181(3): 301-309, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31370003

ABSTRACT

OBJECTIVE: Determine rate of high plasma normetanephrine or metanephrine (PNM-PMN) in a large sample of patients according to PNM-PMN posture and age-adjusted references. DESIGN: Retrospective re-analysis of PNM-PMN from a Canadian reference laboratory (n = 5452), 2011-2015; most were in seated position (n = 5112) rather than supine (n = 340). An international PPGL database demonstrated expected distribution of supine PNM-PMN in PPGL patients. METHODS: All PNM-PMN from a tertiary referral laboratory were reviewed. Any PNM-PMN result greater than 2× upper reference limit (URL) was considered likely true PPGL. Results 1-2× URL were uncertain, requiring additional testing/follow-up despite most being false positive given the rarity of PPGL. The rate of results in the 1-2× URL category were calculated for each group according to collection posture and differing published URL: seated, supine or supine age adjusted. RESULTS: When collected and interpreted by seated URL, 19.6% of PNM required additional testing; only 4.6% being >2× URL. For patients over age 50 years, the abnormal rate was 24.9%. When collected supine, interpreted by supine age-adjusted URL, only 5.3% of PNM were mildly elevated. Possible false positives may be even lower when considering PMN or plasma methoxytyramine which were commonly high in true PPGL despite mild PNM elevations. CONCLUSIONS: In a general medical population, seated PNM has a high rate of abnormal results, far exceeding expected prevalence. Supine measurement with supine, age-adjusted interpretation is strongly preferred prior to costly or invasive PPGL investigations. SUMMARY: Review of 5452 plasma normetanephrine measurements showed 20% to be high, likely false positives for most. Supine, age-adjusted measures were half as likely to be elevated.


Subject(s)
Adrenal Gland Neoplasms/blood , Normetanephrine/blood , Paraganglioma/blood , Pheochromocytoma/blood , Population Surveillance , Sitting Position , Adrenal Gland Neoplasms/diagnosis , Adrenal Gland Neoplasms/epidemiology , Adult , Canada/epidemiology , Female , Humans , Male , Middle Aged , Paraganglioma/diagnosis , Paraganglioma/epidemiology , Pheochromocytoma/diagnosis , Pheochromocytoma/epidemiology , Population Surveillance/methods , Referral and Consultation/trends
15.
J Clin Endocrinol Metab ; 104(11): 5421-5426, 2019 11 01.
Article in English | MEDLINE | ID: mdl-31194241

ABSTRACT

CONTEXT: Current guidelines do not consistently recommend imaging beyond the head and neck region in succinate dehydrogenase subunit D (SDHD) mutation carriers as long as catecholamine metabolite levels are within the reference range. PARTICIPANTS: We report a series of 10 patients carrying pathogenic variants in the SDHD gene from five tertiary referral centers for paraganglioma (PGL) in the Netherlands, who presented with a sympathetic PGL (sPGL), pheochromocytoma (PHEO), or metastases outside the head and neck region in the absence of excessive catecholamine production. Two of six patients with a biochemically silent sPGL/PHEO developed metastatic disease. Additionally, four patients were found to have metastases outside the head and neck region from head and neck PGL. The average interval between the initial diagnosis and discovery of the silent lesions was 10 (range, 0 to 32) years. CONCLUSIONS: The absence of excessive catecholamine production does not exclude the presence of manifestations of SDHD outside the head and neck region. These findings suggest that a more extensive imaging strategy in SDHD mutation carriers may be warranted for detection of biochemically silent lesions.


Subject(s)
Adrenal Gland Neoplasms/genetics , Paraganglioma/genetics , Pheochromocytoma/genetics , Succinate Dehydrogenase/genetics , Adolescent , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/pathology , Adult , Female , Heterozygote , Humans , Male , Middle Aged , Paraganglioma/blood , Paraganglioma/pathology , Pheochromocytoma/blood , Pheochromocytoma/pathology , Young Adult
16.
J Surg Res ; 243: 1-7, 2019 11.
Article in English | MEDLINE | ID: mdl-31146085

ABSTRACT

BACKGROUND: Currently, no reliable predictive clinical or laboratory tests exist that can accurately distinguish between benign and malignant pheochromocytomas or paragangliomas (PPGLs). The aim of this study was to investigate if serum microRNA-210 (miR-210) levels could be a marker of malignancy in patients with PPGLs. METHODS: Preoperative serum from patients with PPGLs was collected on the day of surgery. Clinical demographics, germline mutation status, primary tumor size, postoperative biochemical response, and the development of malignant disease were prospectively collected. Total microRNA was extracted from preoperative serum samples, and miR-210 levels were measured by quantitative real-time reverse transcription-polymerase chain reaction and normalized to miR-16. Prognostic variables were compared using univariable and multivariable analyses. RESULTS: Of the 35 patients, 10 (29%) were diagnosed with malignant PPGLs and 25 patients (71%) were diagnosed with benign PPGLs (median follow-up 72.5 mo). Sixty-nine percent of patients had a pheochromocytoma (n = 24/35) compared with 31% of patients with paraganglioma (n = 11/35). The most common germline mutation was succinate dehydrogenase complex subunit B (SDHB) (n = 10). On univariable analysis, lower serum miR-210 expression level (2.3 ± 0.5 versus 3.1 ± 1.2, P = 0.013) and larger primary tumor size (6.7 ± 5.0 cm versus 4.1 ± 2.3 cm, P = 0.043) were significantly associated with malignant disease. No significant prognostic variables were found on multivariable analysis. CONCLUSIONS: In this pilot study, low serum miR-210 expression levels and large primary tumors were identified to be markers of PPGL malignancy on univariable analysis. Given the initial encouraging results in a small cohort, further investigation is warranted to determine if serum miR-210 levels are prognostic.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Biomarkers, Tumor/blood , MicroRNAs/blood , Paraganglioma/diagnosis , Pheochromocytoma/diagnosis , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/surgery , Adult , Female , Follow-Up Studies , Humans , Logistic Models , Male , Middle Aged , Paraganglioma/blood , Paraganglioma/pathology , Paraganglioma/surgery , Pheochromocytoma/blood , Pheochromocytoma/pathology , Pheochromocytoma/surgery , Pilot Projects , Preoperative Care , Preoperative Period , Prognosis , Prospective Studies , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction
17.
Clin Chim Acta ; 494: 100-105, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30904545

ABSTRACT

BACKGROUND: Availability of appropriately established reference intervals for biochemical tests can be troublesome in pediatrics. Here we establish age-specific continuous reference intervals for catecholamine O-methylated metabolites in children evaluated for catecholamine producing tumors, particularly younger children with suspected neuroblastoma. METHODS: Plasma concentrations of 3-methoxytyramine, normetanephrine, metanephrine, and 3-O-methyldopa were analyzed by liquid chromatography tandem mass spectrometry in 533 children aged 2 days to 18 years. RESULTS: Concentrations of plasma free normetanephrine, 3-methoxytyramine and 3-O-methyldopa were higher in neonates up until six months of age, but thereafter declined steeply to levels after one year that were <38% those of neonatal concentrations and to further lower concentrations in teenagers that were <23% those in neonates. In contrast, concentrations of plasma free metanephrine showed a reciprocal pattern with 50% lower concentrations in infants below one year compared to later in childhood. CONCLUSION: The dynamic reciprocal changes in plasma concentrations of normetanephrine, 3-methoxytyramine and 3-O-methyldopa compared to metanephrine during early childhood suggest underlying developmental changes in extra-adrenal and adrenal chromaffin tissue that must be considered for pediatric reference intervals, particularly in infants. With such reference intervals at hand, biochemical testing for catecholamine producing tumors in young children is substantially improved.


Subject(s)
Adrenal Gland Neoplasms/blood , Aging/blood , Dopamine/analogs & derivatives , Metanephrine/blood , Normetanephrine/blood , Paraganglioma/blood , Pheochromocytoma/blood , Tyrosine/analogs & derivatives , Adolescent , Blood Chemical Analysis , Catecholamines/biosynthesis , Child , Child, Preschool , Chromatography, Liquid , Dopamine/blood , Female , Humans , Infant , Infant, Newborn , Male , Reference Values , Tandem Mass Spectrometry , Tyrosine/blood
18.
Endocrinol Diabetes Nutr (Engl Ed) ; 66(5): 312-319, 2019 May.
Article in English, Spanish | MEDLINE | ID: mdl-30391255

ABSTRACT

INTRODUCTION: Pheochromocytoma and paraganglioma are uncommon tumors whose best known symptoms include high blood pressure, palpitations, headache, and sweating. Clinical identification is not easy, however, and requires biochemical tests that allow for early diagnosis, including measurement of metanephrines levels. The aim of this study was to assess the diagnostic performance of plasma free metanephrines (PMETs) and to verify the transferability of the reference values used. METHODS: PMETs levels were measured by liquid chromatography coupled to tandem mass spectrometry. Other biochemical tests evaluated (plasma catecholamine, urine metanephrine, catecholamine and vanilmandelic acid levels) were performed by liquid chromatography with electrochemical detection. Requests of these tests from 01/09/2015 to 31/10/2017 were reviewed, and both the reference values (document EP28-A3c) and the parameters of biological variation (Fraser method) for PMETs were estimated. RESULTS: The study sample consisted of 1,279 patients (61.3% females) aged 0-90 years, including 19 with pheochromocytoma/paraganglioma. Tests requested included: PMETs (n=662), catecholamines (n=589), metanephrines (n=586), and vanilmandelic acid (n=513) in urine, and plasma catecholamines (n=228). Tests with higher sensitivity were urinary fractionated metanephrines (91.7%) and PMETs (82.4%). When performance was compared in patients with both tests (n=243), they detected the same number of tumors (90.9%), but PMETs showed greater specificity (93.5% vs 88.8%). Plasma normetanephrine levels showed a significant association with age (rho=0.19, P<.0001). CONCLUSION: PMETs and urinary fractionated metanephrines are the biochemical tests with better performance in diagnosis of pheochromocytomas/paragangliomas.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Biomarkers, Tumor/blood , Metanephrine/blood , Paraganglioma/diagnosis , Pheochromocytoma/diagnosis , Adolescent , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/urine , Adult , Age Factors , Aged , Aged, 80 and over , Biomarkers, Tumor/urine , Catecholamines/blood , Catecholamines/urine , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Metanephrine/urine , Middle Aged , Paraganglioma/blood , Paraganglioma/urine , Pheochromocytoma/blood , Pheochromocytoma/urine , Reference Values , Sensitivity and Specificity , Vanilmandelic Acid/urine , Young Adult
19.
Ann Clin Biochem ; 56(1): 163-169, 2019 01.
Article in English | MEDLINE | ID: mdl-30373390

ABSTRACT

BACKGROUND: Patients with mutations of succinate dehydrogenase B (SDHB) and succinate dehydrogenase D (SDHD) are at high risk of paraganglioma necessitating surveillance. Chromogranin A has been proposed as a biochemical marker of paraganglioma. We sought to determine the diagnostic utility of chromogranin A in a population-based SDHx sample. METHODS: Tasmania is an island state with one tertiary referral centre for endocrine neoplasia. We performed a cross-sectional analysis of all adult SDHB ( n = 52) and SDHD ( n = 10) patients undergoing paraganglioma surveillance between 2011 and 2017. Chromogranin A was referenced against the outcome of paraganglioma surveillance with a minimum of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and plasma metanephrines (metanephrine and normetanephrine). RESULTS: Chromogranin A correctly predicted the result of paraganglioma surveillance more often in patients with SDHB compared with those with SDHD (77% vs. 22%, P = 0.003). In the SDHB group, chromogranin A demonstrated a sensitivity of 67% and specificity of 79% compared with 22% and 0% in the SDHD group. Chromogranin A identified one of three PET/CT-visualized SDHB-related paragangliomas with normal plasma metanephrines at the expense of nine false-positive results. A normal chromogranin A demonstrated a negative predictive value of 92% for SDHB-related paraganglioma. In patients with SDHB, plasma normetanephrine and metanephrine offered superior specificity (100%, P = 0.01 and 100%, P < 0.01, respectively) with comparable sensitivity (67%, P = 1.0 and 11%, P = 0.06, respectively) to chromogranin A. CONCLUSION: Chromogranin A does not provide additive benefit to standard surveillance for predicting the presence of SDHB- or SDHD-related paraganglioma, but has a useful negative predictive value when normal in patients with SDHB mutation.


Subject(s)
Biomarkers, Tumor/blood , Chromogranin A/blood , Paraganglioma/diagnosis , Population Surveillance/methods , Adult , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Mutation , Paraganglioma/blood , Paraganglioma/genetics , Succinate Dehydrogenase/genetics , Tasmania
20.
Clin Chem ; 64(11): 1646-1656, 2018 11.
Article in English | MEDLINE | ID: mdl-30097498

ABSTRACT

BACKGROUND: Measurements of plasma or urinary metanephrines are recommended for diagnosis of pheochromocytoma and paraganglioma (PPGL). What test offers optimal diagnostic accuracy for patients at high and low risk of disease, whether urinary free metanephrines offer advantages over deconjugated metanephrines, and what advantages are offered by including methoxytyramine in panels all remain unclear. METHODS: A population of 2056 patients with suspected PPGLs underwent prospective screening for disease using mass spectrometric-based measurements of plasma free, urinary deconjugated, and urinary free metanephrines and methoxytyramine. PPGLs were confirmed in 236 patients and were excluded in others on follow-up evaluation. RESULTS: Measurements of plasma free metabolites offered higher (P < 0.01) diagnostic sensitivity (97.9%) than urinary free (93.4%) and deconjugated (92.9%) metabolites at identical specificities for plasma and urinary free metabolites (94.2%) but at a lower (P < 0.005) specificity for deconjugated metabolites (92.1%). The addition of methoxytyramine offered little value for urinary panels but provided higher (P < 0.005) diagnostic performance for plasma measurements than either urinary panel according to areas under ROC curves (0.991 vs 0.972 and 0.964). Diagnostic performance of urinary and plasma tests was similar for patients at low risk of disease, whereas plasma measurements were superior to both urinary panels for high-risk patients. CONCLUSIONS: Diagnosis of PPGLs using plasma or urinary free metabolites provides advantages of fewer false-positive results compared with commonly measured deconjugated metabolites. The plasma panel offers better diagnostic performance than either urinary panel for patients at high risk of disease and, with appropriate preanalytics, provides the test of choice. Measurements of methoxytyramine in urine show limited diagnostic utility compared with plasma.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Chromaffin Cells/metabolism , Dopamine/analogs & derivatives , Metanephrine , Paraganglioma/diagnosis , Adolescent , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/urine , Adult , Aged , Aged, 80 and over , Dopamine/blood , Dopamine/urine , Female , Follow-Up Studies , Humans , Male , Metanephrine/blood , Metanephrine/urine , Middle Aged , Paraganglioma/blood , Paraganglioma/urine , Predictive Value of Tests , Prospective Studies , ROC Curve , Sensitivity and Specificity , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...